Focus on Metabolism
We're committed to discovering and developing innovative medicines for metabolic diseases. So we focus on creating new treatment options for patients with diabetes, as well as ways to prevent major adverse cardiovascular events in patients with acute coronary syndrome.
While care has improved dramatically over recent years, more than two thirds of cardiovascular events still aren't prevented. As we've developed a deeper understanding of heart disease, research has shown that inflammation plays a central role in the growth and rupture of arterial plaques, which can lead to a coronary event such as heart attack or stroke. We've also seen that lower serum LDL may play a role in reducing the incidence of coronary heart disease. We hope to prevent cardiovascular events by interfering with the inflammation cascade or by impacting LDL target levels.
Recent Accomplishments
-
Molecule: Anti-oxLDL
Anti-oxLDL is a novel full length human IgG1 antibody that is designed to selectively target a specific atherogenic epitope on oxidized LDL (oxLDL). Preclinical studies suggest that there is a strong link between oxLDL and the inflammatory processes that leads to unstable plaque formation in vessel walls. -
Publication: Proc Natl Acad Sci USA, 2010
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes
In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells. View Abstract on PubMed
Pipeline
Genentech's Research and Early Development pipeline has over 25 new molecular entities in clinical development.
